Kaichao Feng
Yao Wang
Weidong Han
Yelei Guo
1. Molecular & Immunological Department, Chinese PLA General Hospital, Beijing 100853, China
2. Bio-therapeutic Department, Chinese PLA General Hospital, Beijing 100853, China
Funds: This research was supported by the grants from the National Natural Science Foundation of China (Grant No. 81230061 to WDH), the Science and Technology Planning Project of Beijing City (No. Z151100003915076 to WDH), the National Key Research and Development Program of China (No. 2016YFC1303501 and 2016YFC1303504 to WDH), and the Nursery Innovation Fund (No. 15KMM50 to YLG).
More InformationCorresponding author: Weidong Han, hanwdrsw69@yahoo.com
Received Date: 2016-12-21
Accepted Date:2017-02-23
Publish Date:2018-01-01
Abstract
Abstract
Cancer stem cells (CSCs), a subpopulation of tumor cells, have self-renewal and multi-lineage differentiation abilities that play an important role in cancer initiation, maintenance, and metastasis. An accumulation of evidence indicates that CSCs can cause conventional therapy failure and cancer recurrence because of their treatment resistance and self-regeneration characteristics. Therefore, approaches that specifically and efficiently eliminate CSCs to achieve a durable clinical response are urgently needed. Currently, treatments with chimeric antigen receptor-modified T (CART) cells have shown successful clinical outcomes in patients with hematologic malignancies, and their safety and feasibility in solid tumors was confirmed. In this review, we will discuss in detail the possibility that CART cells inhibit CSCs by specifically targeting their cell surface markers, which will ultimately improve the clinical response for patients with various types of cancer. A number of viewpoints were summarized to promote the application of CSC-targeted CART cells in clinical cancer treatment. This review covers the key aspects of CSC-targeted CART cells against cancers in accordance with the premise of the model, from bench to bedside and back to bench.Keywords: cancer stem cells,
chimeric antigen receptor,
immunotherapy,
translational medicine,
response evaluation criterion
PDF全文下载地址:
http://www.protein-cell.org/article/exportPdf?id=b79f98e5-a18b-4d2e-8d12-c4f1bd355c49&language=en
